The findings suggest existing therapies for other cancers may be helpful in multiple myeloma (MM). Investigators have identified a biomarker associated with poor outcomes in multiple myeloma (MM) that ...
The Clinical Implications of Basic Research series has focused on highlighting laboratory research that could lead to advances in clinical therapeutics. However, the path between the laboratory and ...
Association of the KRAS genotype and clinicopathologic findings of resected non–small cell lung cancer. Dynamic monitoring circulating tumor DNA in plasma samples by PEAC technology for patients with ...
A subset of breast cancers amplifies the ERBB2 gene at chromosomal region 17q12 and overexpresses its protein product, the ERBB2 tyrosine kinase receptor (also called HER2). This alteration is ...
"This study raises important questions deserving further consideration—notably how the location of the mutation in the HER2 protein and co-occurring mutations may impact the efficacy of HER2-targeting ...
Higher TIL levels in ERBB2-positive breast cancer correlate with improved DDFS and OS, suggesting a prognostic role. Patients with TILs greater than or equal to 20% may safely undergo shorter ...
Not intended for UK and US media Therapy approved based on Phase Ib Beamion LUNG-1 trial data, demonstrating robust efficacy (75.7% objective ...
A team of researchers at Weizmann Institute has regenerated heart cells in adult mice using a specialized protein called ERBB2. When a heart attack strikes, heart muscle cells die and scar tissue ...
Higher tumor-infiltrating lymphocyte (TIL) levels were independently associated with improved overall survival in patients with early-stage ERBB2-positive breast cancer. Each 5% increase in TILs was ...
Neoadjuvant talazoparib (TALA) for operable breast cancer patients with a BRCA mutation (BRCA+). This is an ASCO Meeting Abstract from the 2018 ASCO Annual Meeting I. This abstract does not include a ...
Novel EGFR-sparing, brain-penetrant ErbB2 inhibitor demonstrates superior efficacy profile reaching 80% brain penetrance with potent coverage of key mutations inadequately addressed by currently ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results